Trial Profile
A Phase II Trial of Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate- and High-Risk Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Enoblituzumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Mar 2024 Planned End Date changed from 30 Sep 2023 to 1 Jun 2024.
- 22 Aug 2023 Planned End Date changed from 30 Jul 2023 to 30 Sep 2023.
- 01 Apr 2023 Results published in the Nature Medicine